Literature DB >> 17694083

Histone deacetylases and cancer.

M A Glozak1, E Seto.   

Abstract

Histone deacetylases (HDACs) regulate the expression and activity of numerous proteins involved in both cancer initiation and cancer progression. By removal of acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of genes that encode proteins involved in tumorigenesis. In addition to histones, HDACs bind to and deacetylate a variety of other protein targets including transcription factors and other abundant cellular proteins implicated in control of cell growth, differentiation and apoptosis. This review provides a comprehensive examination of the transcriptional and post-translational mechanisms by which HDACs alter the expression and function of cancer-associated proteins and examines the general impact of HDAC activity in cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17694083     DOI: 10.1038/sj.onc.1210610

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  366 in total

1.  Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Authors:  Anusha Chidambaram; Arunachalam Sekar; Kavya S H; Ramesh Kumar Chidambaram; Kalaiarasi Arunachalam; Senthilkumar G P; Ravikumar Vilwanathan
Journal:  Invest New Drugs       Date:  2017-08-03       Impact factor: 3.850

Review 2.  Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.

Authors:  Günter Schneider; Oliver H Krämer; Roland M Schmid; Dieter Saur
Journal:  J Gastrointest Cancer       Date:  2011-06

3.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

4.  A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.

Authors:  Elisabeth Simboeck; Anna Sawicka; Gordin Zupkovitz; Silvia Senese; Stefan Winter; Franck Dequiedt; Egon Ogris; Luciano Di Croce; Susanna Chiocca; Christian Seiser
Journal:  J Biol Chem       Date:  2010-10-14       Impact factor: 5.157

Review 5.  Unravelling the genomic targets of small molecules using high-throughput sequencing.

Authors:  Raphaël Rodriguez; Kyle M Miller
Journal:  Nat Rev Genet       Date:  2014-10-14       Impact factor: 53.242

6.  Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript.

Authors:  Dairong Feng; Yi Cheng; Yan Meng; Liping Zou; Shangzhi Huang; Jiuyong Xie
Journal:  Genes Nutr       Date:  2015-09-19       Impact factor: 5.523

Review 7.  Customized targeted therapy in Hodgkin lymphoma: hype or hope?

Authors:  Catherine Diefenbach; Ranjana Advani
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

8.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

9.  Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.

Authors:  Annunziata Gloghini; Daniela Buglio; Noor M Khaskhely; Georgios Georgakis; Robert Z Orlowski; Sattva S Neelapu; Antonino Carbone; Anas Younes
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

10.  Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.

Authors:  Bo Cai; Hui Lyu; Jingcao Huang; Shuiliang Wang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Cancer Lett       Date:  2013-02-28       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.